Background. The relationship between concentrations of antituberculosis drugs, sputum culture conversion, and treatment outcome remains unclear. We sought to determine the association between antituberculosis drug concentrations and sputum conversion among patients coinfected with tuberculosis and human immunodeficiency virus (HIV) and receiving first-line antituberculosis drugs.
Tuberculosis infected >10 million persons in 2015 with approximately 1.5 million deaths, of whom 400 000 occurred among persons coinfected with human immunodeficiency virus (HIV) [1] . Clearance of mycobacteria from sputum is necessary to achieve individual cure and decrease tuberculosis transmission; however, up to 50% of patients remain sputum culture positive after 1 month of directly observed therapy, and 20% after 2 months, a fact that has major public health implications for curbing the tuberculosis pandemic [2] [3] [4] . Earlier studies reported that a positive sputum culture after 2 months of treatment is a predictor of treatment failure and tuberculosis relapse [5] . However, more recent studies have demonstrated this finding to be a poor predictor of tuberculosis treatment outcome [6, 7] . Despite this, the sputum culture result at month 2 is used to monitor treatment response and as a marker of the sterilizing activity of antituberculosis drugs [7, 8] . Delayed sputum culture conversion has been associated with high bacillary load at treatment initiation, lung cavities, and drug resistance [9, 10] .
Rifampicin and isoniazid display concentration-dependent killing of mycobacteria, leading to a decrease in bacillary load within the first few days of treatment [11] . Several studies have demonstrated low antituberculosis drug concentrations in patients receiving tuberculosis treatment [12] [13] [14] . At present, there is conflicting evidence about whether there is an association between antituberculosis drug concentrations, time to sputum conversion, and tuberculosis treatment outcome [14] [15] [16] .
The aim of the current study was to determine the association between antituberculosis drug concentrations and sputum conversion in a cohort of tuberculosis-HIV-coinfected patients receiving first-line antituberculosis drugs at the standard dosage.
METHODS

Setting
We carried out a prospective observational study entitled Study on Outcomes Related to TB and HIV Drug Concentrations among tuberculosis-HIV-coinfected patients from May 2013 to November 2015 at the Infectious Diseases Institute (IDI) in Kampala, Uganda.
Study Design and Population
Tuberculosis was diagnosed using a combination of clinical symptoms (cough for ≥2 weeks, a history of fever as reported by the patient, unintended weight loss of ≥10% in the previous 3 months, and night sweats) and findings of chest radiography, sputum florescent microscopy, cultures, and Xpert MTB/ RIF assay. All patients had a documented Uni-Gold test result confirming HIV infection. HIV-infected patients with pulmonary tuberculosis diagnosed were included in the study if they were ≥18 years old, willing to comply with study visits, and had no prior history of tuberculosis treatment. Details of the study methods were published elsewhere [17] .
Patients were excluded if they (1) required tuberculosis treatment for >6 months (eg, for tuberculous meningitis); (2) had been previously treated for infections due to mycobacteria other than Mycobacterium tuberculosis; (3) were pregnant; (4) had an elevated alanine aminotransferase level >5 times the upper limit of normal; (5) had a glomerular filtration rate <50 mL/min, which could affect drug elimination; or (6) had comorbid conditions that reduce life expectancy to <1 year (eg, visceral Kaposi sarcoma). Patients were withdrawn from the study on request, based on medical judgment of the study physician, if they became pregnant, experienced a toxic effect necessitating a change or interruption of tuberculosis treatment, had a drug sensitivity test result showing resistance to any first-line antituberculosis drug (which could delay sputum conversion), or had only mycobacteria other than M. tuberculosis identified in the baseline culture.
Tuberculosis treatment was provided according to World Health Organization (WHO) recommendations [14] using fixed-dose combinations, which included 2 months (intensive phase) of rifampicin, isoniazid, ethambutol, and pyrazinamide (RHEZ), followed by 4 months (continuation phase) of isoniazid and rifampicin with dosages based on weight bands: 3 tablets of RHEZ or isoniazid-rifampicin for weight <55 kg, 4 tablets for weight 55-69 kg, and 5 tablets for weight ≥70 kg. Each tablet contained 150 mg of rifampicin, 75 mg of isoniazid for both RHEZ and isoniazid-rifampicin combinations plus 400 mg of pyrazinamide and 275 mg of ethambutol for RHEZ. Antiretroviral treatment (ART) consisting of tenofovir, lamivudine, and efavirenz was started ≥2 weeks after initiation of tuberculosis treatment, as long as the patient was willing to commence treatment. Patients who were already receiving ART at the time of tuberculosis diagnosis continued their treatment, and patients taking nevirapine were switched to efavirenz to reduce drug-drug interactions. Patients receiving protease inhibitors received rifabutin instead of rifampicin and were therefore excluded from this analysis.
Pharmacokinetic Measurements
Patients were followed up at 2, 8, and 24 weeks after initiation of tuberculosis treatment and fasted for ≥8 hours before the study visit. At each follow-up visit, blood sampling was performed at 0 hours (before drug ingestion) and 1, 2, and 4 hours after witnessed ingestion of antituberculosis drugs. A standardized meal was provided after the 1-hour blood collection. Adherence counseling was performed at every follow-up visit. Adherence was assessed through pill counts and self-report using 7-day and 1-month recall [18] .
Blood samples were collected in serum Vacutainer test tubes, and serum was separated by centrifuging within 1 hour of the blood sampling. Serum concentrations of rifampicin, isoniazid, pyrazinamide, and ethambutol were measured at the IDI translational laboratory in Kampala using UV high-performance liquid chromatography, as described elsewhere [19] . Additional information on the methods are available in the Supplementary Material.
Microbiological Assessment
A spot sputum sample was requested at every follow-up visit for fluorescent microscopy, as well as culture using both Löwenstein-Jensen medium and the BACTEC Mycobacteria Growth Indicator Tube 960 system. In accordance with the standard of care, sputum microscopy was also performed after 5 months of tuberculosis treatment. Patients who could not spontaneously provide a sputum sample underwent sputum induction where possible.
After a substudy protocol amendment was approved, the last 108 study participants underwent intensive sputum culture monitoring. This subset of patients provided sputum samples for microscopy and culture every 2 weeks for the first 12 weeks of treatment. All other procedures were identical to those performed in the rest of the study population.
Ethical Considerations
Ethical approval was received from Joint Clinical and Research Centre Institutional Review Board, Uganda National Council for Science and Technology (reference No. HS1303) and the National Drug Authority. This study is registered in Clinicaltrials.gov (NCT01782950). Written informed consent was obtained from all study participants.
Assessment of Outcome
Tuberculosis treatment outcomes were defined according to the WHO treatment guidelines [14] . Sputum culture conversion was defined as conversion of sputum cultures from positive to negative with no subsequent positive cultures in patients with a positive culture at baseline. Participants were considered lost to follow-up if their tuberculosis treatment outcome or clinical status was unknown by the end of the follow-up period (6 months after completion of tuberculosis treatment).
Data Analysis
We included patients who had a positive sputum culture at baseline, were followed up prospectively, and had pharmacokinetic data available on ≥1 occasion. The estimated maximum drug concentration (eC max ) for each drug was defined as the highest concentration of the 1-, 2-, and 4-hour blood samples at each study visit. Population pharmacokinetic models were developed using Monolix software [20] and individual area under the concentration-time curves (AUC) over 24 hours were derived from these models. Details of these models can be found in the Supplementary Material.
We used time-to-event analyses (Kaplan-Meier curves and Cox proportional hazards regression) to determine factors associated with sputum culture conversion. Predictors of low drug concentrations and the status of cured versus not cured were determined with logistic general estimation equations accounting for multiple time points with pharmacokinetic determinations per patient. WHO weight bands were divided into 3 equal tertiles (upper, middle, and lower) as one predictor of low concentrations. Wilcoxon rank-sum tests were used to assess associations between the eC max of each drug and baseline characteristics. We determined the number of drugs and proportions of patients with an eC max below the lower limit of the reference ranges for each participant, using thresholds from Peloquin et al [21] : 3 mg/L for isoniazid, 8 mg/L for rifampicin, 20 mg/L for pyrazinamide, and 2 mg/L for ethambutol [21, 22] . We also evaluated the recent maximum drug concentration (C max ) and AUC thresholds from Pasipanodya et al [23] : 8.8 mg/L and 52 mg · h/L to isoniazid, 6.6 mg/L and 13 mg· h/L for rifampicin, 58.3 mg/L and 363 mg· h/L for pyrazinamide.
A drug was classified as below the cutoff if the eC max was below the reference range on the study visit when sputum culture conversion was established or below the reference range on ≥1 study visit before sputum culture conversion. For patients without conversion by the end of tuberculosis treatment, we used the eC max from the last study visit, and for those conversion, we used the lowest eC max among the values below the threshold. For analysis of AUCs, we used the lowest AUC before or at the time of sputum conversion or the AUC from the last study visit for those who without conversion by the end of tuberculosis treatment. Our hypothesis was that patients with antituberculosis drug concentrations below the reference ranges were more likely to have delayed sputum culture conversions than those with normal concentrations. All analyses were performed using Stata software (version 14.2; StataCorp).
RESULTS
Patient Demographics
From April 2013 to May 2015, a total of 294 HIV-infected patients were screened for the study, and 268 were enrolled. Forty-one patients (15.3%) were excluded from the analysis: 30 had negative sputum smears and cultures throughout the study, 4 had no prospective follow-up data, and 7 had no pharmacokinetic data (3 of whom were taking rifabutin) (Figure 1) . Patients who were excluded had a lower median CD4 cell count (190/µL vs 76/µL; P = .02). The other characteristics of excluded patients are provided in the Supplementary Data.
We included 227 patients with a median follow-up of 182 person-years in our final analysis; 134 patients (59%) were male, the median age (interquartile range [IQR]) was 34 (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) Table 2) .
Attainment of Therapeutic Targets for Antituberculosis Drugs
The overall median eC max for isoniazid and rifampicin were below the lower limits of the reference ranges [21] We compared our median eC max and AUC findings to new targets set by Pasipanodya et al [23] . All but 1 participant had an isoniazid eC max and AUC below those recommended by Pasipanodya et al. In the case of rifampicin, none of the participants had an AUC below the target recommended by Pasipanodya et al, but 136 of 222 (61.3%) had an eC max below the new recommended target. The majority of the participants (222 of 224) had a pyrazinamide eC max less than the new recommended target, and 59 of 224 (26.3%) had a lower pyrazinamide AUC (Figure 2 ).
Pharmacokinetics and Sputum Culture Conversion
Using thresholds published by Peloquin et al [21] , patients with low eC max for isoniazid or rifampicin were less likely to have sputum culture conversion before the end of tuberculosis treatment (HR, 0.54; 95% CI, .37-.77; P = .001) or by the end of follow-up (0.61; .44-.85; P = .003) ( Table 5 ). Patients with ≥1 drug below the cutoff were also less likely to have sputum conversion than those who had no drug below the cutoff, after adjustment for age, BMI, and sex (Table 3) . In the subgroup analysis of 108 patients in whom sputum smears and cultures were obtained every 2 weeks, 69% were male, with a median (IQR) age of 35 (30- Patients with low isoniazid and rifampicin concentrations had a <10% probability of remaining culture positive by the end of follow-up ( Figure 3 ). The median times to sputum conversion among those with no drug, 1, or >1 drug below the cutoff were 1 (IQR, 1-1), 5 (I3-7), and 9 (7-11) weeks, respectively. Every 1-mg· h/L increment in AUC of rifampicin or isoniazid led to a 2%-4% increase in the likelihood of having sputum conversion (HR, 1.02 [95% CI, 1.01-1.02] P = .01] for rifampicin and 1.04 [1.02-1.06; P < .001] for isoniazid). Patients in the highest AUC quartile for rifampicin and for isoniazid were approximately twice as likely to experience sputum conversion by the end of follow-up as those in the lowest AUC quartile (Table 5 ). Using target concentrations for pyrazinamide described by Pasipanodya et al [23] , we found no association between the AUC of pyrazinamide and time to sputum conversion (HR, 0.9; 95% CI, .7-1.32; P = .86) ( Table 3) .
Tuberculosis Treatment Outcomes
Of the 227 patients, 158 (70%) were cured, 10 (4.4%) had treatment failure, and 17 (7.5%) were withdrawn from the study ( Figure 1 ). All patients lost to follow-up had experienced sputum culture conversion before the end of follow-up. Of those who were withdrawn or transferred out, 20 of 31 (64.5%) had experienced sputum conversion, and 8 (72%) of the 11 patients who died had sputum culture conversion. Patients with eC max values below the cutoff for both isoniazid and rifampicin had a moderately increased risk of unfavorable treatment outcomes, including death, failure, loss to follow-up, and default (odds ratio, 1.09; 95% CI, 1.01-1.17; P = .02). Those weighing <55 kg were also more likely to have unfavorable treatment outcomes (Table 4) .
DISCUSSION
We found an association between low concentrations of isoniazid and rifampicin and delayed sputum culture conversion. Our findings are consistent with recent studies, which have demonstrated that higher exposures of rifamycins are associated with faster sputum clearance and a higher proportion of patients with negative cultures after 8 weeks of treatment [24, 25] . Delayed sputum culture conversion may have implications for tuberculosis transmission, especially in settings such as ours in sub-Saharan Africa, because patients are not isolated during tuberculosis treatment.
Others have also reported the association between drug concentrations and sputum conversion. In a retrospective study in predominantly HIV-uninfected participants [26] and a prospective study in which >50% of participants were HIV infected [27] , patients with a low isoniazid eC max were more likely to remain culture positive at week 8. Contrary to this finding, Chang and colleagues [15] and van Crevel and colleagues [16] found no association between C max of rifampicin and sputum culture conversion. The conflicting evidence may be attributed to the variability in study population and study design, including different sampling time points. In addition, when correlating concentrations with treatment response, the fact that drug concentrations in blood may not be reflective of concentrations at the site of activity (eg, lung tissue) should be taken into account.
Despite the high proportion of patients with low isoniazid and rifampicin concentrations, few patients had tuberculosis treatment failure (4.4%). However, low concentrations of both isoniazid and rifampicin were associated with unfavorable outcomes, which included death, failure, loss to follow-up, and default. Other prospective observational studies reported an association between low concentrations of pyrazinamide [28] , isoniazid [27, 29] , and rifampicin [29] and unfavorable tuberculosis treatment outcome. Although patients in the lower weight bands were not at risk of lower drug concentrations and actually received a relatively higher dose per kilogram than those in the higher weight bands (who were slightly underdosed), they had worse outcomes. This finding may be attributed to several factors, including the fact that patients in lower weight band may be sicker than those in higher weight bands. Association between number of drugs below the cutoff and time to sputum culture conversion in 108 patients with intensive sputum culture monitoring. KaplanMeier curves for these patients demonstrate the probability of remaining sputum culture positive over time, stratified by the number of drug concentrations below the lower limit of the normal reference range for rifampicin (<8 mg/L) and isoniazid (<3 mg/L). Hazard ratios (HRs) are shown with 95% confidence intervals in parentheses.
We evaluated other thresholds, including those proposed by Pasipanodya et al [23] . The proposed targets for isoniazid were achieved in almost none of our participants, whereas all of them had AUCs above the proposed targets for rifampicin. Although the target AUC for pyrazinamide was achieved in 74% of our participants, only 21% achieved this target in a study by Alsultan et al [30] . These proposed thresholds still need to be evaluated prospectively. Different thresholds for rifampicin (<3.01 mg/L) and pyrazinamide (<38.1 mg/L) were associated with treatment failure and death in children with mostly extrapulmonary tuberculosis. Therefore, the site of tuberculosis may contribute to the difference in study findings and high variability in pharmacokinetic parameters [31] .
The limitations of our study include our use of the total drug concentrations, and yet it is the free drug that is pharmacologically active. The AUC/minimum inhibitory concentration (MIC) and C max /MIC have been shown by others to be useful predictors of culture conversion [32, 33] . Lack of MIC data limits our ability to further evaluate pharmacokinetic/pharmacodynamic markers of sputum conversion and tuberculosis treatment outcomes. Sturkenboom and colleagues [34] described variability in the C max of rifampicin (0.4-5.7 hours), and several studies have demonstrated variability in the C max of isoniazid based on N-acetyltransferase polymorphisms; therefore, sampling up to 4 hours after dosing may have limited the accuracy of the pharmacokinetic parameter estimates [34, 35] . We did not evaluate the effect of drug concentrations on relapse, which has been associated with low pyrazinamide concentrations [23, 28] .
The merits of our study include its large sample size, its prospective design with a large body of clinical data, and the pharmacokinetic sampling done on 3 occasions (at 2, 8, and 24 weeks) and with 3 time points (1, 2, and 4 hours), which enabled us to have a close approximation of the eC max and develop models for AUCs. With intensive monitoring of sputum cultures we were able to give a more accurate estimate of the time to sputum conversion in a subset of the population. In conclusion, although low isoniazid and rifampicin concentrations in this HIV-tuberculosis-coinfected population did not translate into high proportions of patients with treatment failure, the association between low concentrations of isoniazid and rifampicin and prolonged sputum culture positivity has implications for tuberculosis transmission and warrants further investigation.
